Nureca Limited Announces Merger with Wholly Owned Subsidiary and Strike-Off of Another

2 min read     Updated on 24 Jul 2025, 11:55 AM
scanx
Reviewed by
Naman SharmaScanX News Team
whatsapptwittershare
Overview

Nureca Limited approves merger with wholly owned subsidiary Nureca Technologies Private Limited, aiming to streamline operations and boost shareholder value. The merger, subject to regulatory approvals, involves Nureca Limited (Revenue: Rs 1,146.40 crores, Net Worth: Rs 1,917.38 crores) and Nureca Technologies Private Limited (Revenue: Rs 228.14 crores, Net Worth: Rs 53.94 crores). Benefits include improved efficiency, reduced overheads, and simplified group structure. Additionally, Nureca Limited approves strike-off of non-material subsidiary Nureca Healthcare Private Limited. No new shares will be issued, and shareholding pattern remains unchanged.

14883936

*this image is generated using AI for illustrative purposes only.

Nureca Limited , a prominent player in the healthcare and medical equipment sector, has announced significant corporate restructuring moves aimed at streamlining operations and enhancing shareholder value.

Merger with Nureca Technologies Private Limited

The Board of Directors of Nureca Limited has approved a draft scheme for the merger by absorption of its wholly owned subsidiary, Nureca Technologies Private Limited. This strategic decision, made on May 20, 2025, is subject to necessary statutory and regulatory approvals.

Financial Snapshot

The financial details of both entities involved in the merger are as follows:

Company Revenue (FY 2025) Net Worth (as of March 31, 2025)
Nureca Limited Rs 1,146.40 crores Rs 1,917.38 crores
Nureca Technologies Private Limited Rs 228.14 crores Rs 53.94 crores

Rationale Behind the Merger

The merger is expected to bring several benefits to the company and its stakeholders:

  1. Improved operational efficiency
  2. Elimination of inter-corporate dependencies
  3. Minimization of administrative compliances
  4. Maximization of shareholder value through reduced overheads
  5. Simplification of the group structure

It's important to note that no new shares will be issued as part of this scheme, and there will be no change in the shareholding pattern of Nureca Limited.

Strike-Off of Nureca Healthcare Private Limited

In addition to the merger, Nureca Limited has also approved the strike-off of another wholly owned subsidiary, Nureca Healthcare Private Limited. This subsidiary is described as non-material and non-functional.

The company stated that the strike-off of Nureca Healthcare Private Limited will contribute to achieving a simplified corporate structure, uniformity in corporate policy, and reduction of entities in the group. This move is expected to decrease managerial overlaps and increase overall efficiency.

Regulatory Compliance

As per the SEBI Listing Regulations, Nureca Limited has filed the necessary documents with the stock exchanges for dissemination. These include:

  1. Copy of the Scheme of Merger
  2. Outcome of the Board Meeting approving the Draft Scheme
  3. Certified True Copy of the Extract of the Resolution passed by the Board of Directors

The company has emphasized that the merger scheme is exempt from obtaining a 'No Objection Letter' from the Stock Exchange, as it involves the merger of a wholly owned subsidiary with its holding company.

Conclusion

These strategic moves by Nureca Limited reflect the company's commitment to optimizing its corporate structure and enhancing operational efficiency. As the healthcare sector continues to evolve, such restructuring efforts may position Nureca Limited to better capitalize on market opportunities and drive long-term growth.

Investors and stakeholders will be keenly watching the progress of these corporate actions and their impact on the company's future performance.

Historical Stock Returns for Nureca

1 Day5 Days1 Month6 Months1 Year5 Years
+0.13%-1.01%-4.18%+5.41%-35.92%-64.26%

Nureca Reports Strong Q4 Growth, Expands Distribution, and Outlines Strategic Priorities for FY26

2 min read     Updated on 05 May 2025, 10:50 PM
scanx
Reviewed by
ScanX News Team
whatsapptwittershare
Overview

Nureca Limited's Q4 FY25 revenue increased by 87% to ₹317.50 crore, with EBITDA rising 156% to ₹32.00 crore. Full-year FY25 results show 19.3% revenue growth and 1,480.6% EBITDA growth. The company partnered with Swiggy for quick commerce expansion and completed FDA registration for its manufacturing facility. Strategic priorities for FY26 include manufacturing expansion, quick commerce leadership, product innovation, and export growth.

8011236

*this image is generated using AI for illustrative purposes only.

Nureca Limited , a leading player in the home healthcare and wellness industry, has reported impressive financial results for the fourth quarter of fiscal year 2025, along with significant strategic developments.

Strong Financial Performance

For Q4 FY25 (January-March 2025), Nureca's revenue surged by 87% to ₹317.50 crore, compared to ₹169.70 crore in the same quarter last year. This robust growth was accompanied by a significant improvement in profitability, with EBITDA rising by 156% to ₹32.00 crore, up from ₹-57.00 crore in Q4 FY24.

The company's full-year results for FY25 also showed positive momentum:

Metric FY25 FY24 YoY Growth
Revenue ₹1,096.61 ₹919.28 19.3%
EBITDA ₹49.00 ₹3.10 1,480.6%

Expansion of Distribution Channels

In a strategic move to enhance its market reach, Nureca has entered into a new agreement with Swiggy, a leading quick commerce player. This partnership aims to ensure faster product availability, improve customer satisfaction, and expand Nureca's market presence. The company's products are already available on other major quick commerce platforms such as Blinkit and Zepto.

Manufacturing Milestone

Nureca Technologies Private Limited, the manufacturing arm of Nureca Limited, has successfully completed its annual registration with the U.S. Food and Drug Administration (FDA) for its 510(k)-exempt medical devices. This registration allows the company to continue manufacturing and exporting medical devices to the United States from its Mohali, Punjab facility, reflecting Nureca's commitment to maintaining high regulatory standards and expanding its global presence.

Strategic Priorities for FY26

Looking ahead, Nureca has outlined several key strategic priorities for the fiscal year 2026:

  1. Manufacturing Expansion: The company plans to operationalize and scale production at its Punjab facility to support both local and export markets.

  2. Quick Commerce Leadership: Nureca aims to deepen partnerships, expand its product assortment, and optimize fulfillment models for quick commerce platforms.

  3. Innovation Pipeline: The company will focus on launching new health, wellness, and fitness SKUs aligned with emerging consumer needs.

  4. Export Growth: Leveraging its US FDA certifications, Nureca intends to expand into North American and Middle Eastern markets.

Management Commentary

Saurabh Goyal, Chairman and Managing Director of Nureca Limited, expressed his gratitude to shareholders for their continued confidence in the company. He stated, "We are excited about the opportunities that lie ahead and are committed to delivering strong results in the coming quarters."

As Nureca continues to strengthen its position in the home healthcare and wellness sector, the company's focus on expanding its distribution channels, enhancing manufacturing capabilities, and driving innovation positions it well for sustained growth in the evolving healthcare landscape.

Historical Stock Returns for Nureca

1 Day5 Days1 Month6 Months1 Year5 Years
+0.13%-1.01%-4.18%+5.41%-35.92%-64.26%
More News on Nureca
Explore Other Articles
230.78
+0.30
(+0.13%)